Corporate Overview
PDS Biotech is a clinical stage biopharmaceutical company with a growing pipeline of cancer immunotherapies and infectious disease vaccines. Our team is committed to developing first-in-class T cell activating immunotherapies to fight against cancer and to provide more rapid and longer-lasting protection against infectious diseases.
| 3 | Proprietary T cell activating platforms |
| 4 | Ongoing Phase 2 clinical trials |
| World class partnerships |
With Merck, MD Anderson Cancer Center, National Cancer Institute and Mayo Clinic |
Latest News
Corporate Presentation
Upcoming Events
|
01 Oct |
PDS0101 Oral Presentation of Cervical Cancer Data at ASTRO 2023 |
|
03 Oct |
Current and Future Treatments for Recurrent/Metastatic HPV-Positive HNSCC and the Potential Application of PDS0101 KOL Roundtable |
|
18 Oct |
PDS0301 Oral Presentation of Prostate Cancer Data at Cytokines 2023 |
|
22 Oct |
PDS0101 Presentation of HNSCC Data at ESMO Annual Meeting |
Quick Links
SEC Filings
Governance
Documents
Stock Info
Analyst Coverage
FAQs